Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Alexandra S. Zimmer, Seth M. Steinberg, Dee Dee Smart, Mark R. Gilbert, Terri S. Armstrong, Eric Burton, Nicole Houston, Nadia Biassou, Brunilde Gril, Priscilla K. Brastianos, Scott L. Carter, David Lyden, Stanley Lipkowitz, Patricia S. Steeg
Abstract
Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).